Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy

被引:0
|
作者
Tsavaris, N [1 ]
Mylonakis, N [1 ]
Bacoyiannis, C [1 ]
Kosmas, C [1 ]
Kalergis, G [1 ]
Iakovidis, V [1 ]
Tzaninis, D [1 ]
Kosmidis, P [1 ]
机构
[1] Metaxa Canc Hosp, Dept Med Oncol 2, Piraeus 18537, Greece
关键词
antiemetic activity; metoclopramide; cisplatin;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some clinical parameters play a role in developing effective antiemetic therapy. In the present study, 310 patients entered and 301 were evaluable. They received cisplatin based combination chemotherapy (100 mg/m(2)), with antiemetic therapy based in metoclopramide, at a standard dose and schedule (2 mg/kg in 5 doses). Patient characteristics such as age, sex, performance status (Karnofsky), site of primary tumor, weight loss >15%, previous chemotherapy, previous radiotherapy, history of vomiting during pregnancy, additional drugs (dexamethasone, alprazolam), in the antiemetic regimen were included in the evaluation. We also studied the manifestation of anxiety and depression and the presence of psychosocial problems related to therapy, evaluated them with specific psychological indexes modified for our study. We evaluated incidence of vomiting, retches, and nausea, with several scales. We distinguished three groups of factors influencing nausea and vomiting. Factors that predicted for increased nausea and vomiting was gender (women), stress and age (younger patients experienced more prolonged duration and higher grades of nausea). The addition of alprazolam (a sedative drug) and dexamethasone, was associated with decreased incidence of nausea and vomiting. The weight loss (increased nausea and decreased vomiting control according to Gralla's scale). Previous chemotherapy decreased the number of patients without nausea and vomiting control according to Gralla's scale. Patients with previous radiotherapy presented an increased grade of nausea. Patients with head and neck cancer presented less nausea with shorter duration, less frequent episodes of vomiting. Patients with ovarian cancer presented increased mean number of retches. In conclusion, despite difficulties in assessing nausea and vomiting among clinical trials, several factors, especially stress, gender, weight loss, additional drugs (corticosteroids and sedatives) may play an important role in modulating the antiemetic response.
引用
收藏
页码:1147 / 1155
页数:9
相关论文
共 50 条
  • [41] COMPARISON OF ANTIEMETIC EFFICACY OF DOMPERIDONE, METOCLOPRAMIDE, AND DEXAMETHASONE IN PATIENTS RECEIVING OUTPATIENT CHEMOTHERAPY REGIMENS
    CUNNINGHAM, D
    EVANS, C
    GAZET, JC
    FORD, H
    POPLE, A
    DEARLING, J
    CHAPPELL, D
    COOMBES, C
    BRITISH MEDICAL JOURNAL, 1987, 295 (6592): : 250 - 250
  • [42] ANTIEMETIC EFFICACY OF MODERATELY HIGH-DOSE METOCLOPRAMIDE IN PATIENTS RECEIVING VARYING DOSES OF CISPLATIN - CONTROLLED COMPARISON WITH A COMBINATION OF METHYLPREDNISOLONE AND METOCLOPRAMIDE
    ELL, C
    KONIG, HJ
    BROCKMANN, P
    DOMSCHKE, S
    DOMSCHKE, W
    ONCOLOGY, 1985, 42 (06) : 354 - 357
  • [43] Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin
    Hashizume, Junya
    Higuchi, Norihide
    Sato, Kayoko
    Kodama, Yukinobu
    Matsunaga, Noriko
    Sakamoto, Toshiaki
    Yamaguchi, Kentaro
    Nakamura, Tadahiro
    Kitahara, Takashi
    Sasaki, Hitoshi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (04) : 611 - 614
  • [44] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy of a triple antiemetic combination in cancer patients receiving cisplatin-based chemotherapy: TRIPLE Pharmacogenomics Study
    Suzuki, K.
    Tsuji, D.
    Yokoi, M.
    Daimon, T.
    Nakao, M.
    Ayuhara, H.
    Kogure, Y.
    Shibata, K.
    Hayashi, T.
    Takeda, K.
    Nishio, M.
    Hama, T.
    Itoh, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S231 - S231
  • [45] Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas
    Tsukahara, Kiyoaki
    Nakamura, Kazuhiro
    Motohashi, Ray
    Sato, Hiroki
    Endo, Minoru
    Katsube, Yasuaki
    Ueda, Yuri
    Suzuki, Mamoru
    ACTA OTO-LARYNGOLOGICA, 2014, 134 (11) : 1198 - 1204
  • [46] ANTIEMETIC EFFECT OF ORAL VERSUS INTRAVENOUS METOCLOPRAMIDE IN PATIENTS RECEIVING CISPLATIN - A RANDOMIZED, DOUBLE-BLIND TRIAL
    ANTHONY, LB
    KROZELY, MG
    WOODWARD, NJ
    HAINSWORTH, JD
    HANDE, KR
    BRENNER, DE
    GRECO, FA
    BURISH, TG
    JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) : 98 - 103
  • [47] ENHANCEMENT OF THE ANTIEMETIC ACTION OF METOCLOPRAMIDE AGAINST CISPLATIN-INDUCED EMESIS BY TRANSDERMAL ELECTRICAL NERVE-STIMULATION
    SALLER, R
    HELLENBRECHT, D
    BUHRING, M
    HESS, H
    JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (02): : 115 - 119
  • [48] ANTIEMETIC ACTIVITY OF TERTACOSACTIDE IN PATIENTS UNDER FAC CHEMOTHERAPY
    BONNETERRE, J
    JOVENIAUX, A
    DEGUINE, O
    ADENIS, L
    SEMAINE DES HOPITAUX, 1984, 60 (48-4): : 3347 - 3349
  • [49] Antiemetic activity of megestrol acetate in patients receiving chemotherapy
    Zang, Jian
    Hou, Min
    Gou, Hong Feng
    Qiu, Meng
    Wang, Jing
    Zhou, Xiao Juan
    Luo, De Yun
    Yang, Yu
    Jiang, Ming
    Cao, Dan
    Bi, Feng
    Xu, Feng
    Shen, YaLi
    Yi, Cheng
    SUPPORTIVE CARE IN CANCER, 2011, 19 (05) : 667 - 673
  • [50] Antiemetic activity of megestrol acetate in patients receiving chemotherapy
    Jian Zang
    Min Hou
    Hong Feng Gou
    Meng Qiu
    Jing Wang
    Xiao Juan Zhou
    De Yun Luo
    Yu Yang
    Ming Jiang
    Dan Cao
    Feng Bi
    Feng Xu
    YaLi Shen
    Cheng Yi
    Supportive Care in Cancer, 2011, 19 : 667 - 673